These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28190247)

  • 1. PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.
    Croessmann S; Wong HY; Zabransky DJ; Chu D; Rosen DM; Cidado J; Cochran RL; Dalton WB; Erlanger B; Cravero K; Button B; Kyker-Snowman K; Hurley PJ; Lauring J; Park BH
    Breast Cancer Res Treat; 2017 Apr; 162(3):451-464. PubMed ID: 28190247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
    Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
    Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
    Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
    Moon WK; Chen HH; Shin SU; Han W; Chang RF
    Magn Reson Imaging; 2019 Nov; 63():60-69. PubMed ID: 31425802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
    Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
    Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
    Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer.
    R HC; Kumar S U; R G; Naayanan PJ; Sathiyarajeswaren P; Devi MSS; K SS; Doss C GP
    J Cell Biochem; 2023 Feb; 124(2):188-204. PubMed ID: 36563059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
    Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
    Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A microscopic landscape of the invasive breast cancer genome.
    Ping Z; Xia Y; Shen T; Parekh V; Siegal GP; Eltoum IE; He J; Chen D; Deng M; Xi R; Shen D
    Sci Rep; 2016 Jun; 6():27545. PubMed ID: 27283966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers.
    Resteghini C; Perrone F; Miceli R; Bergamini C; Alfieri S; Orlandi E; Guzzo M; Granata R; Galbiati D; Cavalieri S; Locati L; Licitra L; Bossi P
    Tumori; 2018 Jun; 104(3):213-220. PubMed ID: 29714670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population.
    Huang Q; Zhou Y; Wang B; Zhao Y; Zhang F; Ding B
    BMC Med Genomics; 2022 Jul; 15(1):146. PubMed ID: 35778737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions.
    Delmonico L; Costa MASM; Fournier MV; Romano SO; Nascimento CMD; Barbosa AS; Moreira ADS; Scherrer LR; Ornellas MHF; Alves G
    Ann Diagn Pathol; 2019 Apr; 39():30-35. PubMed ID: 30634138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
    Yang H; Shu Z; Jiang Y; Mao W; Pang L; Redwood A; Jeter-Jones SL; Jennings NB; Ornelas A; Zhou J; Rodriguez-Aguayo C; Bartholomeusz G; Iles LR; Zacharias NM; Millward SW; Lopez-Berestein G; Le XF; Ahmed AA; Piwnica-Worms H; Sood AK; Bast RC; Lu Z
    Clin Cancer Res; 2019 Sep; 25(18):5702-5716. PubMed ID: 31391192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
    Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
    Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperative oncogenic effect and cell signaling crosstalk of co‑occurring HER2 and mutant PIK3CA in mammary epithelial cells.
    Dong L; Meng F; Wu L; Mitchell AV; Block CJ; Zhang B; Craig DB; Jang H; Chen W; Yang Q; Wu G
    Int J Oncol; 2017 Oct; 51(4):1320-1330. PubMed ID: 28902361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.